The issue of addiction linked to Ultra-Processed-Food-based nutrition, leading to chronic metabolic diseases like obesity, is under scrutiny by many research groups
GLP-1 medications work by slowing digestion, reducing hunger and helping your body regulate appetite more effectively
Meanwhile, other neurons only experienced temporary increases, possibly because they internalized or degraded their GLP-1 receptors, the authors explained
To summarize, while it is already clear that GLP-1based therapies will be an integral part of the treatment of DKD owing to their metabolic, cardiovascular, and kidney effects, exciting times lie ahead, with the ongoing development of compounds that will have potentially greater effects on these outcomes, due to more pronounced effects on body weight and glycemia